Aversi-Pharma (შპს ავერსი-ფარმა)

panel 2026-09-21Ask

separate · GEL, thousands

Line item	2017	2018	2019	2020	2021	2022	2023	2024	CAGR
Total Revenue	366,150	409,571	456,542	508,166	690,807	737,781	825,680	980,306	+15.1%
	233,736	257,100	281,733	317	429	470,970	520,278	628,105	+15.2%
Gross Profit	132,414	152,471	174,809	507,849	690,378	266,811	305,402	352,201	+15.0%
Gross Margin	36.2%	37.2%	38.3%	99.9%	99.9%	36.2%	37.0%	35.9%
	6,943	12,750	3,834	5,091	4,936	4,343	2,985	4,972	-4.7%
	106,968	120,814	118,375	114,019	160,467	186,598	215,350	246,898	+12.7%
EBITDA	32,389	44,407	60,268	398,921	534,847	84,556	93,037	110,275	+19.1%
EBITDA Margin	8.8%	10.8%	13.2%	78.5%	77.4%	11.5%	11.3%	11.2%
Total D&A	13,046	15,337	24,839	26,945	30,319	36,163	39,421	44,917	+19.3%
EBIT / Operating Income	19,343	29,070	35,429	371,976	504,528	48,393	53,616	65,358	+19.0%
Total Interest Income	2,457	3,053	1,541	2,027	2,308	3,087	4,761	5,412	+11.9%
Total Interest Expense	2,311	2,902	7,231	6,345	5,935	5,099	4,643	5,815	+14.1%
	3,140	3,585	6,508	22,458	15,150	21,728	533	1,771	nmf
Profit Before Tax	22,629	32,806	23,231	345,200	516,051	68,109	53,201	63,184	+15.8%
Total Income Tax	0	1,566	838	399	329	0	0	0	nmf
Net Profit / (Loss)	22,629	34,372	19,336	26,206	82,740	61,348	53,201	63,184	+15.8%
Net Margin	6.2%	8.4%	4.2%	5.2%	12.0%	8.3%	6.4%	6.4%

Aversi-Pharma